Illumina, Inc. $ILMN Shares Sold by Stephens Inc. AR

Stephens Inc. AR trimmed its stake in Illumina, Inc. (NASDAQ:ILMN) by 12.6% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 6,505 shares of the life sciences company’s stock after selling 942 shares during the quarter. Stephens Inc. AR’s holdings in Illumina were worth $621,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in ILMN. Rise Advisors LLC grew its position in shares of Illumina by 173.6% in the first quarter. Rise Advisors LLC now owns 353 shares of the life sciences company’s stock valued at $28,000 after purchasing an additional 224 shares during the period. Golden State Wealth Management LLC grew its position in shares of Illumina by 123.2% in the first quarter. Golden State Wealth Management LLC now owns 529 shares of the life sciences company’s stock valued at $42,000 after purchasing an additional 292 shares during the period. Caitong International Asset Management Co. Ltd grew its position in shares of Illumina by 2,936.8% in the first quarter. Caitong International Asset Management Co. Ltd now owns 577 shares of the life sciences company’s stock valued at $46,000 after purchasing an additional 558 shares during the period. WPG Advisers LLC purchased a new stake in shares of Illumina in the first quarter valued at $58,000. Finally, Blue Trust Inc. grew its position in shares of Illumina by 63.1% in the second quarter. Blue Trust Inc. now owns 654 shares of the life sciences company’s stock valued at $62,000 after purchasing an additional 253 shares during the period. Hedge funds and other institutional investors own 89.42% of the company’s stock.

Illumina Price Performance

Shares of NASDAQ ILMN opened at $100.11 on Friday. Illumina, Inc. has a 1-year low of $68.70 and a 1-year high of $156.66. The business has a 50-day moving average of $98.17 and a 200-day moving average of $91.65. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.81 and a quick ratio of 1.41. The company has a market capitalization of $15.39 billion, a price-to-earnings ratio of 12.67, a PEG ratio of 2.47 and a beta of 1.40.

Illumina (NASDAQ:ILMN) last issued its earnings results on Thursday, July 31st. The life sciences company reported $1.19 earnings per share for the quarter, topping the consensus estimate of $1.02 by $0.17. Illumina had a return on equity of 28.93% and a net margin of 29.36%.The company had revenue of $1.06 billion during the quarter, compared to the consensus estimate of $1.12 billion. During the same quarter in the prior year, the business earned $0.36 earnings per share. The company’s revenue was down 4.8% compared to the same quarter last year. Illumina has set its FY 2025 guidance at 4.450-4.55 EPS. On average, equities analysts anticipate that Illumina, Inc. will post 4.51 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on ILMN shares. Canaccord Genuity Group lifted their price objective on Illumina from $99.00 to $105.00 and gave the company a “hold” rating in a research report on Friday, August 1st. Daiwa Capital Markets downgraded Illumina from an “outperform” rating to a “neutral” rating and set a $94.00 price objective for the company. in a research report on Tuesday, August 12th. Evercore ISI lowered their price objective on Illumina from $135.00 to $132.00 and set an “outperform” rating for the company in a research report on Tuesday, October 7th. Scotiabank downgraded Illumina from a “sector outperform” rating to a “sector perform” rating and set a $125.00 price target for the company. in a research report on Friday, July 11th. Finally, Stephens set a $110.00 price target on Illumina and gave the company an “overweight” rating in a research report on Monday, August 4th. Five investment analysts have rated the stock with a Buy rating, eleven have given a Hold rating and three have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $115.25.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.